One morning in early 2026, sunlight streamed through pristine laboratory windows, bathing the Shanghai facilities of WuXi AppTec Bioanalytical Services (BAS). Researchers were engrossed in their work, and precision instruments operated smoothly.

What set this day apart was the arrival of two special guests: on-site auditors from the College of American Pathologists (CAP).

The researchers maintained their focus amidst the audit. They calibrated instruments and prepared reagents with practiced ease. Real-time project timelines were displayed on computer screens as they carried out routine operations.

The auditors moved freely between workstations, reviewing records, verifying procedures, and examining data with minimal unnecessary dialogue.

When the auditors closed their assessment files, the result was expected: zero critical findings and successful completion of the audit.

Treating the Audit as a "Comprehensive Check-up" on Quality

This successful CAP audit is by no means an isolated achievement. Since the establishment of WuXi AppTec Bioanalytical Services in 2005, its affiliated laboratories have repeatedly completed quality system and project-level inspections conducted by major global regulatory bodies, including the National Medical Products Administration (NMPA, formerly CFDA), the U.S. Food and Drug Administration (FDA), the Organisation for Economic Co-operation and Development (OECD), the European Medicines Agency (EMA), the College of American Pathologists (CAP), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. This string of verified accomplishments stands as a solid testament to the team’s long-term commitment to upholding rigorous quality systems.

Asked how the team consistently meets the rigorous standards of global regulatory authorities, Ms. Ying Tong, Head of Bioanalytical Services China at WuXi Testing, stated with simple determination, "Our principle is ‘any time is ready’."

In daily operations, the Bioanalytical Services team constantly asks itself one question: Can every project completed today withstand scrutiny from any future audit? Guided by this philosophy, the team has embedded data integrity, traceability, and compliance requirements into every step of routine workflows from the very design of its quality system.

In Ying’s view, auditors are not there to “find fault”—they are reviewers conducting a “health check” that verifies compliance of existing quality systems and project execution, while uncovering opportunities for improvement. As such, the Bioanalytical Services team has always welcomed each audit with an open, proactive mindset.

This composure also stems from the team’s strict attention to every detail. Even for procedures not mandated by industry standards or regulatory requirements, the team consistently strives for excellence. Take critical data review as an example: although dual-person verification is not obligatory for certain steps, the team has proactively incorporated this workflow to safeguard the accuracy of experimental data.

Such meticulous attention to detail has earned high recognition from regulatory bodies. During several OECD audit, the inspection team praised WuXi AppTec Bioanalytical Services for its mature GLP framework and strong quality, highlighting continuous refinement in quality systems, document management, data recording, and archiving. The inspectors particularly commended the proactive compliance of standard operating procedures (SOPs) for computerized system validation, as well as the transparency and traceability of records.

“When every detail is held to the highest standard, we earn the trust of regulators and clients,” Ying adds.

This commitment to quality is also a microcosm of the entire WuXi AppTec quality system. In 2025, the company completed a total of 741 quality audits and inspections, including 680 audits by customers, 56 inspections by regulatory authorities, and 5 audits by independent third parties—all with zero critical findings.

Quality by Design: Aligning with Global Regulatory Expectations

Since its founding, WuXi AppTec has strictly adhered to global regulations and technical guidance. A core strength of the Bioanalytical Services team is its ability to operate seamlessly under multiple regulatory frameworks and rigorous professional accreditation standards.

“Different regulators focus on different priorities,” Ying explains. “Our quality systems ensure that all projects operate under corresponding compliant workflows.”

As an integral part of WuXi AppTec’s integrated CRDMO platform, Bioanalytical Services team deeply embodies the company’s corporate-wide strategy of Quality by Design (QbD). This philosophy is not merely a slogan, but a core corporate strategy deeply integrated into the operational practices of every global site. From project initiation, stringent quality controls are pre-built into every stage, ensuring processes remain audit-ready at all times.

Under this top-down framework, the Bioanalytical Services team demonstrates agility in adapting to global regulations. For complex cross-region filing needs, the team follows the principle of “One Rule for All”, integrating stringent requirements from the FDA, NMPA, EMA, and other agencies directly into process design. For instance, when a project requires simultaneous regulatory submissions across Asia, North America and Europe, the Bioanalytical Services team can rapidly develop a unified testing framework that aligns with multiple global standards, drawing on the company’s extensive expertise and accumulated experience. This ensures seamless, globally compliant project execution.

This system-wide capability provides clients with greater confidence and predictability. Choosing WuXi AppTec means partnering with a mature quality framework already rigorously vetted by leading global authorities. It not only mitigates risks of repeat experiments due to divergent standards but also significantly reduces timeline uncertainty from audits—acting as a safeguard for the efficiency of clients’ drug development programs.

Meanwhile, frequent global audits in turn fuel the continuous evolution of quality systems. The Bioanalytical Services team treats each inspection as an opportunity to review and optimize workflows, streamlining and enhancing processes based on the latest regulatory expectations. This virtuous cycle of external assessment, reflection and iterative enhancement enables WuXi AppTec to deliver a reassuring, hassle-free experience for clients, achieving robust guarantees for both quality and operational efficiency.

Digital Enabling: Achieving Speed and Stability in Routine Operations

"Fast and reliable"—this is the consistent acclaim WuXi AppTec receives from its clients. At WuXi AppTec, speed and quality are not mutually exclusive.

When asked how the Bioanalytical Services team achieves this balance, Ying shares the team’s approach: “Quality and efficiency are not contradictory. Digitalization, scientific process design, and lean management enable us to uphold quality standards while boosting productivity—making speed and stability our standard model.”

At WuXi AppTec's 2025 Investor Day, the Bioanalytical Services team's digital-driven efficiency initiatives were presented as an example of the company's lean operations: through its digital management platform, WuXi AppTec Bioanalytical Services reduced turnaround times for bottleneck steps by 30% and shortened analytical durations by 35%.

These results are driven by three core digital strategies:

• Real-time visualization of project milestones, breaking down information silos and enabling full progress transparency;
• Automated data flow and audit trails, minimizing manual intervention and human error while ensuring end-to-end data traceability;
• Proactive risk early warning, shifting from a reactive “manual bottleneck detection” model to a system-driven approach that flags risks ahead of time and prevents delays at the source.

As Ying emphasizes: “Our efficiency comes from standardization and digitalization—never from compromising on quality steps.”

Beyond SOPs: Understanding the “Why”

While technological upgrades and system integration are critical, execution ultimately depends on people. WuXi AppTec’s record for high-quality delivery is built on uniformly rigorous quality standards across global sites, implemented consistently to meet both regulatory requirements and client needs. This alignment and execution are fostered through company-wide training, an established quality culture, and ongoing peer learning, knowledge sharing, and collaboration.

Ying notes: “Writing policies or SOPs is straightforward. The real challenge is helping every employee understand why these steps are mandatory. Grasping the rationale behind the system is what matters most.”

Only when teams understand the intent of regulations can they adapt and improve as circumstances evolve. This understanding is not achieved through one-off training, but cultivated through daily mentorship, repeated discussions, and problem-solving—gradually forming internalized discipline and routine behaviors.

This philosophy also defines the new-hire development program. To ensure new staff deliver high-quality work, the Bioanalytical Services team has implemented a rigorous proficiency testing system: new-hires complete simulated assays and mock studies, and must meet all performance benchmarks before independently undertaking client-assigned work.

“New hires are the future of our quality system. We must guard this gateway,” Ying states.

Guided by Science, Illuminating the Path of Innovation

As WuXi AppTec Bioanalytical Services has integrated stringent quality requirements into its daily operational fundamentals, the tide of industry development brings new challenges. The fast-growing development of novel molecular therapies such as new type of peptides, oligonucleotides, and XDC conjugates poses new challenges for bioanalytical science.

Regulations and technical standards for these innovative drug molecules are still evolving, with a few areas remaining in an exploratory phase where no established standards exist. Facing such new challenges, the Bioanalytical Services team adheres to three principles: grounded in scientific rationale, bounded by risk control, and aligned with global regulatory expectations.

“Standards may take time to mature, but scientific logic cannot be compromised,” Ying states. “Even when formal regulations are not yet published, we design rigorous processes based on sound scientific principles.”

One example is a specialized bioanalytical platform at WuXi AppTec Bioanalytical Services, for which no formal bioanalytical method validation or sample analysis guidelines yet exist. Even so, the team proactively established rigorous internal quality standards and well-defined procedures. In a recent first comprehensive regulatory audit of this testing platform, the platform received zero critical findings.

Beyond that, during NMPA audits, the team proactively captures the key focus areas of inspectors and emerging regulatory trends to identify opportunities for optimizing quality management, ensuring the team keeps pace with evolving regulations and pre-emptively strengthens compliance controls.

“Twenty years ago, we were building quality systems. Today, we use these systems to power complex innovation,” Ying reflects. As the industry evolves, the boundaries of bioanalysis continue to expand—from traditional drug testing to novel therapeutic development, from single-stage testing to end-to-end compliance management. Throughout this journey, one thing remains unchanged: the team’s unwavering commitment to quality and respect for science.

The glow of the setting sun falls gently on the focused faces of laboratory scientists. Instruments run steadily, continuously generating authentic and reliable data sets. For the Bioanalytical Services team, every rigorously validated data point contributes to the reliable evidence package that supports the approval of a new medicine, bringing hope and light to patients suffering from disease.

On the long journey of new drug development, bioanalysis serves as a meticulous guardian safeguarding quality throughout the process. Guided by the vision of "every drug can be made, and every disease can be treated", WuXi AppTec Bioanalytical Services team meets every test with composure, adapts to diverse global standards with professional expertise, and upholds uncompromising dedication to every detail.